Basic information Physical Form Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Lumateperone

Lumateperone

Basic information Physical Form Safety Supplier Related

Lumateperone Basic information

Product Name:
Lumateperone
Synonyms:
  • ITI-722
  • Lumateperone
  • ITI-722 lumateperone
  • 1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3‘,4‘:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-one
  • 313368-91-1Lumateperone(ITI-007)
  • 1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-
  • 1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one
  • 1-(4-Fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone
CAS:
313368-91-1
MF:
C24H28FN3O
MW:
393.5
Product Categories:
  • API
Mol File:
313368-91-1.mol
More
Less

Lumateperone Chemical Properties

Boiling point:
556.4±50.0 °C(Predicted)
Density 
1.26±0.1 g/cm3(Predicted)
pka
9.10±0.20(Predicted)
form 
Oil
color 
Colorless to light yellow
InChIKey
HOIIHACBCFLJET-SFTDATJTSA-N
SMILES
C(C1=CC=C(F)C=C1)(=O)CCCN1C[C@@]2([H])C3=CC=CC4=C3N([C@@]2([H])CC1)CCN4C
More
Less

Lumateperone Usage And Synthesis

Physical Form

white solid

Description

Lumateperone is a novel antipsychotic agent with a unique mechanism of action with high 5-hydroxytryptamine 2A(5-HT2A) blocking activity. A Phase 2 study in treatment of insomnia revealed strong evidence of efficacy, with no impairment of next-day cognition.

Uses

Lumateperone was a drug developed for the treatment of schizophrenia. May have applications in bipolar depression.

Synthesis

Synthesis of Lumateperone

in vivo

Lumateperone (i.p., 1-10 mg/kg) promotes NMDA and AMPA-induced currents in a dopamine D1 receptor-dependent manner and increases the release of dopamine and glutamate in rat mPFC slices[2].

Animal Model:Adult male Sprague-Dawley rats[2]
Dosage:1-10 mg/kg
Administration:Intraperitoneal injection
Result:Inhibited avoidance response at concentrations of 1, 3 and 10 mg/kg after 20 minutes.
Promoted NMDA and AMPA-sensitive currents, also significantly increased dopamine and glutamate release at 10 mg/kg in mPFC cone cells of rat.

IC 50

D1 Receptor; D2 Receptor

storage

Store at 0-8℃

References

[1] Patent: US2004/220178, 2004, A1

LumateperoneSupplier

Taizhou Yuxin Biotechnology Co., Ltd., Gold
Tel
+86-0576--88902229 +86-13968687450
Email
yuxin@yuxchem.com
Shanghai Famo Bio-chemical Technology Company Ltd. Gold
Tel
021-02136680027 15800370750
Email
1706640024@qq.com
Jinan Sanyuan Chemical Co. LTD Gold
Tel
0531-58582194; 18615587029
Email
1660423085@qq.com
Hangzhou Chemtrue Bio-Tech Co.,Ltd. Gold
Tel
0571-86828652 18857119830
Email
sales@chemtrue-bio.com
Chengdu Aupone Pharmaceutical Co.,Ltd. Gold
Tel
18980796919
Email
236656639@qq.com